cGAS-STING Inhibitor Companies for Neurodegeneration

Overview

This category page covers biotechnology and pharmaceutical companies developing therapies that target the cGAS-STING (cyclic GMP-AMP synthase - Stimulator of Interferon Genes) pathway for the treatment of neurodegenerative diseases, particularly [Parkinson's disease](/diseases/parkinsons-disease) and [Alzheimer's disease](/diseases/alzheimers-disease).

The cGAS-STING pathway is a cytosolic DNA sensing mechanism that triggers type I interferon responses. In neurodegenerative diseases, activation of this pathway contributes to [neuroinflammation](/mechanisms/neuroinflammation-parkinsons) and neuronal death through multiple mechanisms:

• Mitochondrial DNA (mtDNA) release into cytoplasm
• Nuclear DNA (nDNA) escape due to nuclear envelope dysfunction
• Chronic activation of microglia
• Type I interferon response induction

Pipeline Overview

| Company | Drug | Mechanism | Stage | Indication |
|---------|------|-----------|-------|------------|
| Denali Therapeutics | DNL787 | STING antagonist | Preclinical | PD, AD |
| Nodthera | NT-0896 | cGAS/STING dual inhibitor | Preclinical | Neurodegeneration |
| Vedanta Biosciences | VE707 | STING modulator | Research | PD, AD |

Key Companies

Denali Therapeutics

• Focus: STING pathway inhibition
• Lead Candidate: DNL787
• Indication: Parkinson's disease, Alzheimer's disease
• Stage: Preclinical
• Mechanism: Brain-penetrant STING antagonist
• Notes: Leveraging their Brain Transport Vehicle (BTV) platform for CNS delivery

...

Overview

This category page covers biotechnology and pharmaceutical companies developing therapies that target the cGAS-STING (cyclic GMP-AMP synthase - Stimulator of Interferon Genes) pathway for the treatment of neurodegenerative diseases, particularly [Parkinson's disease](/diseases/parkinsons-disease) and [Alzheimer's disease](/diseases/alzheimers-disease).

The cGAS-STING pathway is a cytosolic DNA sensing mechanism that triggers type I interferon responses. In neurodegenerative diseases, activation of this pathway contributes to [neuroinflammation](/mechanisms/neuroinflammation-parkinsons) and neuronal death through multiple mechanisms:

• Mitochondrial DNA (mtDNA) release into cytoplasm
• Nuclear DNA (nDNA) escape due to nuclear envelope dysfunction
• Chronic activation of microglia
• Type I interferon response induction

Pipeline Overview

| Company | Drug | Mechanism | Stage | Indication |
|---------|------|-----------|-------|------------|
| Denali Therapeutics | DNL787 | STING antagonist | Preclinical | PD, AD |
| Nodthera | NT-0896 | cGAS/STING dual inhibitor | Preclinical | Neurodegeneration |
| Vedanta Biosciences | VE707 | STING modulator | Research | PD, AD |

Key Companies

Denali Therapeutics

• Focus: STING pathway inhibition
• Lead Candidate: DNL787
• Indication: Parkinson's disease, Alzheimer's disease
• Stage: Preclinical
• Mechanism: Brain-penetrant STING antagonist
• Notes: Leveraging their Brain Transport Vehicle (BTV) platform for CNS delivery

Denali has a strong foundation in lysosomal biology and has been expanding into innate immune pathways. Their STING program builds on expertise in neuroinflammation and microglial biology.

Nodthera Ltd.

• Focus: NLRP3/cGAS-STING dual inhibition
• Lead Candidate: NT-0896
• Indication: Neurodegenerative diseases
• Stage: Preclinical
• Mechanism: Dual inhibitor targeting both NLRP3 inflammasome and cGAS-STING pathways
• Notes: Expanding beyond NLRP3-only focus to address multiple inflammatory pathways

Nodthera, known for their NLRP3 inhibitor NT-0796 in Phase 1/2 for AD, is developing next-generation compounds that target both NLRP3 and cGAS-STING pathways given their synergistic roles in neuroinflammation.

Vedanta Biosciences

• Focus: STING modulation
• Lead Candidate: VE707
• Indication: Parkinson's disease, Alzheimer's disease
• Stage: Research
• Mechanism: STING pathway modulator
• Notes: Exploring microbiome-derived approaches to immune modulation

Vedanta Biosciences is known for their expertise in immune modulation and live biotherapeutic products. Their STING program represents an expansion into neurodegenerative disease.

Research Compounds and Tool Molecules

The following compounds are widely used in research but have not yet reached clinical development for neurodegeneration:

| Compound | Mechanism | Developer/Source | Notes |
|----------|-----------|------------------|-------|
| H-151 | Covalent STING inhibitor | Research compound | Prevents STING palmitoylation |
| C-176 | STING antagonist | Research compound | Blocks STING trafficking |
| C-178 | STING inhibitor | Research compound | Neuroprotection in models |
| GYS1460 | STING antagonist | Research | Reduces neuroinflammation in PD models |
| RU.521 | cGAS antagonist | Research compound | Selective for cGAS |

Mechanism of Action

cGAS-STING Pathway in Neurodegeneration

Therapeutic Approaches

| Target | Approach | Companies | Stage |
|--------|----------|-----------|-------|
| cGAS | Direct inhibition | Nodthera | Preclinical |
| STING | Antagonist | Denali | Preclinical |
| TBK1 | Kinase inhibition | Research | Research |
| Type I IFN | Receptor blockade | Research | Research |

Competitive Landscape

The cGAS-STING field for neurodegeneration is emerging, with companies positioning themselves:

| Company | Primary Focus | STING Program Status |
|---------|---------------|---------------------|
| Denali Therapeutics | CNS delivery | Preclinical |
| Nodthera | Dual inflammasome/STING | Preclinical |
| Vedanta Biosciences | Immune modulation | Research |

Comparison with Neuroinflammation Companies

| Mechanism | Key Companies | Stage | Notable |
|-----------|---------------|-------|----------|
| NLRP3 Inflammasome | Nodthera, Olatec | Phase 1-2 | NT-0796 |
| TREM2 | Alector, Denali | Phase 1-2 | AL002 |
| TNF-α | INmune Bio | Phase 2 | XPro1595 |
| cGAS-STING | Denali, Nodthera | Preclinical | DNL787 |

Clinical Trial Landscape

Currently, no cGAS-STING inhibitors have reached clinical trials for neurodegenerative diseases. The field is in preclinical development with several programs expected to enter Phase 1 within the next 2-3 years.

Cross-Links to Related Pages

Mechanism Pages

• [cGAS-STING Inhibitors for Parkinson's](/mechanisms/cgas-sting-inhibitors-parkinsons)
• [cGAS-STING Pathway in PD](/mechanisms/cgas-sting-parkinsons)
• [cGAS-STING in Neurodegeneration](/mechanisms/cgas-sting-neurodegeneration)
• [Neuroinflammation in PD](/mechanisms/neuroinflammation-parkinsons)
• [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction-parkinsons)

Gene/Protein Pages

• [cGAS Gene](/genes/cgas)
• [STING Gene](/genes/sting1)
• [TBK1 Gene](/genes/tbak1)

Company Pages

• [Denali Therapeutics](/companies/denali-therapeutics)
• [Nodthera Ltd.](/companies/nodthera)
• [Vedanta Biosciences](/companies/vedanta-biosciences)
• [Alzheimer's Neuroinflammation Companies](/companies/ad-neuroinflammation-companies)
• [AD cGAS-STING and Innate Immune Companies (AD-specific)](/companies/ad-cgas-sting-innate-immune-companies)

Disease Pages

• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Alzheimer's Disease](/diseases/alzheimers-disease)

Research and Development Challenges

Blood-Brain Barrier Penetration

Many STING antagonists have limited CNS penetration. Companies are developing brain-penetrant formulations:

• Denali's BTV platform
• Nodthera's brain-penetrant chemistry
• Nanoparticle delivery systems

Target Validation

• Genetic evidence linking STING polymorphisms to PD risk
• Preclinical knockout data showing neuroprotection
• Biomarker development (cGAMP levels in CSF)

Temporal Dynamics

• Optimal timing of intervention in disease progression
• Distinguishing primary vs. secondary pathway activation

Investment Perspective

The cGAS-STING pathway represents an emerging target in neuroinflammation with several advantages:

Genetic validation: GWAS links STING polymorphisms to PD risk

Mechanistic clarity: Clear pathway from DNA release to neuroinflammation

Combination potential: Can be combined with other anti-inflammatory or disease-modifying approaches

Challenges include:

• Limited CNS-penetrant clinical candidates
• Competition from established neuroinflammation targets (NLRP3, TREM2)
• Early stage of development

See Also

• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Neuroinflammation Mechanisms](/mechanisms/neuroinflammation)
• [Investment Landscape: Neuroinflammation](/investment/neuroinflammation-therapeutics)
• [Emerging Novel Mechanism AD Companies](/companies/emerging-novel-mechanism-ad-companies-2024-2025)

References

[cGAS-STING Inhibitors for Parkinson's Disease](/mechanisms/cgas-sting-inhibitors-parkinsons)

[Hopfner KP et al., cGAS-STING pathway in neurodegeneration (2018)](https://pubmed.ncbi.nlm.nih.gov/30531920/)

[Sliter DA et al., STING and neurodegeneration (2018)](https://pubmed.ncbi.nlm.nih.gov/29930140/)

[Wang Q et al., Novel STING antagonists in PD (2024)](https://pubmed.ncbi.nlm.nih.gov/38538876/)